MPO and rheumatoid arthritis: Active MPO and/or its products such as HOCl-modified proteins, 3-chlorotyrosine and GSA, are upregulated at sites of inflammation in cardiovascular disease and atherosclerotic lesions, RA joints, and lungs of patients with cystic fibrosis and inflammatory and fibrotic kidney disease [12, 29, 46–49].